Thymopentin vs HBD-2
Head-to-head comparison of Thymopentin (L-Arginyl-L-Lysyl-L-Aspartyl-L-Valyl-L-Tyrosine) and HBD-2 (Human Beta-Defensin 2) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Thymopentin | HBD-2 |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | L-Arginyl-L-Lysyl-L-Aspartyl-L-Valyl-L-Tyrosine | Human Beta-Defensin 2 |
| Molecular Weight | 676.78 Da | 4316 Da |
| Half-Life | 10-30 min | Minutes to hours; protease-sensitive |
| Amino Acids | 5 | 41 |
| Typical Dose | 1 mg | Research use only; no approved human dose |
| Route | Subcutaneous | Topical / Intranasal / Research parenteral |
| Purity | ≥98% | ≥98% |
| Studies Count | 90 | 420 |
| Research Status | Clinical | Pre-clinical |
Thymopentin Benefits
- ✓t-cell maturation
- ✓helper-suppressor balance
- ✓immune recovery
- ✓antiviral-adjunct research
HBD-2 Benefits
- ✓broad-spectrum antimicrobial activity
- ✓epithelial barrier defense
- ✓innate immune modulation
- ✓anti-biofilm potential
Thymopentin Dosing
1 mg SC or IM|2-3x weekly|4-8 week study cycles
HBD-2 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Thymopentin Side Effects
- ⚠injection-site redness
- ⚠mild fever
- ⚠headache
HBD-2 Side Effects
- ⚠local irritation at high concentrations
- ⚠proteolytic instability
- ⚠potential pro-inflammatory signaling
Research Overview
Thymopentin
Thymopentin has a long history of preclinical and clinical investigation as a thymic peptide immunomodulator. Published studies report effects on T-cell subsets, cytokine responses, and immune recovery in recurrent infection settings.
HBD-2
Human beta-defensin 2 has been studied extensively for direct microbicidal effects and for its role in shaping mucosal immunity. Preclinical work shows activity against Gram-negative and Gram-positive organisms, with additional effects on leukocyte recruitment and wound defense.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.